Single-arm, Prospective Clinical Study of PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 28 May 2025 Status changed from not yet recruiting to recruiting.
- 04 Jun 2024 New trial record